Use of porcine acellular dermal matrix as a dermal substitute in rats.

Objective: To examine porcine acellular dermal matrix (ADM) as a xenogenic dermal substitute in a rat model.

Summary Background Data: Acellular dermal matrix has been used in the treatment of full-thickness skin injuries as an allogenic dermal substitute providing a stable wound base in human and animal studies.

Methods: Xenogenic and allogenic ADMs were produced by treating porcine or rat skin with Dispase and Triton X-100.

Long-term outcome of xenogenic dermal matrix implantation in immunocompetent rats.

Background: Acellular dermal matrix (ADM) has been used successfully in the treatment of full-thickness skin injuries as an allogenic dermal substitute. To assess the efficacy of xenogenic ADM in such wounds, we examined the long-term wound healing and immunological responses to porcine ADM in a rat model.

Materials And Methods: Xenogenic and allogenic ADMs were produced by treating porcine (fresh or cryopreserved) or rat skin with dispase and Triton X-100.

Xenogeneic acellular dermal matrix as a dermal substitute in rats.

Acellular dermal matrix (ADM) has been used as a dermal substitute for the treatment of deep burns, but the availability of cadaver skin for the production of ADM is limited. The usefulness of porcine ADM as a xenogeneic dermal substitute in rats was studied. With the use of Dispase II (Boehringer Mannheim, Indianapolis, Ind) and Triton X-100 (US Biochemicals, Cleveland, Ohio), xenogeneic ADM was prepared from commercially available, cryopreserved porcine skin, and allogeneic ADM from the rats was also prepared.